Untitled Document
[an error occurred while processing this directive]
www.expresspharmaonline.com FORTNIGHTLY INSIGHT FOR PHARMA PROFESSIONALS
16 - 31 May 2011  
Untitled Document
Sections

Market
Management
Pharma Ally
Pharma Life
Research
Pharma Technology Review

Specials

Express Biotech

Services
Editorial Advisory Board
Open Forum
Subscribe/Renew
Archives
Search
Media Kit
Contact Us
Network Sites
Express Computer
Express Channel Business
Express Hospitality
Express TravelWorld
Express Healthcare
Group Sites
ExpressIndia
Indian Express
Financial Express

[an error occurred while processing this directive]

[an error occurred while processing this directive]

[an error occurred while processing this directive]
Home - Market - Article

Piramal Healthcare diversifies its business

Our News Bureau - Mumbai

Piramal Life Sciences Ltd (PLSL) and Piramal Healthcare Ltd (PHL)announced that the boards of both the companies considered and approved the demerger scheme of arrangement between PLSL and PHL. Also, Piramal Healthcare entered into financial services sector by acquiring Indiareit Fund Advisors Pvt Ltd and Indiareit Investment Management company for a consideration of Rs. 225 crore.

Under the proposed demerger scheme, the New Chemical Entity (NCE) research unit of PLSL would be demerged into PHL with effect from April 1, 2011 which shall be the appointed date under the demerger scheme. All assets and liabilities of the NCE division will be transferred to PHL at book value.

Since, April 2007, when PLSL was demerged from PHL as an independent discovery research company, it has made significant progress. The pipeline of R&D programmes has increased from nine to 24 with nine additional programme moving into phase I/II clinical trials and two additional programme moving into phase II clinical trials. During this time, PLSL has also received Rs. 135 million towards milestone payment from collaboration with Eli Lilly & Company.

The development projects from pipeline would need strong financial support going forward. Hence the Board of PLSL has approved the demerger of NCE Research unit into PHL. The herbal products division that markets neutraceutical products to less regulated markets globally will continue to be with PLSL.

Through this demerger, PHL will have an access to an innovation platform of PLSL through which it can build its Innovative discovery and commercialisation business. PHL can also avail 200 per cent weighted average deduction both on operational expense and capital expenditure on R&D work.

 


[an error occurred while processing this directive]
404 - Error: 404

An error has occurred.
The requested page cannot be found.

If difficulties persist, please contact the System Administrator of this site and report the error below.

#404 Category not found


[an error occurred while processing this directive]
[an error occurred while processing this directive]
[an error occurred while processing this directive]
[an error occurred while processing this directive]
[an error occurred while processing this directive]

FEEDBACK: We would love to hear from you -- what you like about our content, what you dont, and even how you think we can improve. Please send your feedback to: editorial.ep@expressindia.com


Copyright 2001: The Indian Express Limited. All rights reserved throughout the world. This entire site is compiled in Mumbai by the Business Publications Division (BPD) of The Indian Express Limited. Site managed by BPD.